June 23, 2026Journal of the American College of Cardiology
Profound inhibition of platelet aggregation with monoclonal antibody 7E3 Fab thrombolytic therapy
Key result
m7E3 Fab cuts major bleeding ~50% and improves coronary patency in acute MI with rt-PA.
- n=70
Why the study?
Does m7E3 Fab improve platelet inhibition and coronary patency without increasing bleeding in patients with acute myocardial infarction receiving thrombolytic therapy?
Population
70 patients with acute myocardial infarction receiving recombinant tissue-type plasminogen activator…
Comparison
Murine-derived monoclonal antibody 7E3 Fab bolus… vs Control subjects receiving rt-PA, aspirin, and…
Design
Cohort
Authors
Discussion
Loading...
Member takes
Implication
The addition of m7E3 Fab to thrombolytic therapy in acute myocardial infarction safely achieves profound platelet inhibition and may improve coronary patency.
Key Points
- The study aims to evaluate the safety and physiological activity of monoclonal antibody 7E3 Fab in patients receiving thrombolytic therapy for acute myocardial infarction.
- Sixty patients treated with rt-PA, aspirin, and heparin received m7E3 Fab at 3, 6, and 15 hours after treatment.
- Ten control patients received rt-PA without m7E3 Fab to compare the outcomes.
- Key measures included platelet aggregation, bleeding events, and coronary artery patency.
- Maximal platelet aggregation inhibition occurred at a dose of 0.25 mg/kg of m7E3 Fab.
- Major bleeding was observed in 25% of m7E3 Fab-treated patients vs. 50% in controls; bleeding often coincided with bypass surgery.
- Coronary artery patency was significantly higher in m7E3 Fab-treated patients (92% vs. 56% in controls).
Structured PICO
Does m7E3 Fab improve platelet inhibition and coronary patency without increasing bleeding in patients with acute myocardial infarction receiving thrombolytic therapy?
P
Population
70 patients with acute myocardial infarction receiving rt-PA, aspirin, and heparin.
I
Intervention
Murine-derived monoclonal antibody 7E3 Fab (m7E3 Fab) bolus injections in ascending doses at 3, 6, and 15 hours after initiation of thrombolytic infusion
C
Comparator
Control subjects receiving rt-PA, aspirin, and heparin but not m7E3 Fab
O
Outcome
Physiologic activity (receptor site blockade and inhibition of platelet aggregation) and safety (major bleeding)surrogate
Main Result
Absolute Event Rate: 25% vs 50%
The addition of m7E3 Fab to thrombolytic therapy in acute myocardial infarction safely achieves profound platelet inhibition and may improve coronary patency.
Cite This Study
Kleiman et al. (1993) studied acute myocardial infarction (n=70). murine-derived monoclonal antibody 7E3 Fab (m7E3 Fab) vs. rt-PA, aspirin and heparin without m7E3 Fab was evaluated on major bleeding. In patients with acute myocardial infarction receiving rt-PA, m7E3 Fab resulted in major bleeding in 25% of patients versus 50% in controls, and a 92% coronary patency rate versus 56% in controls.